Brokerages Set MDxHealth SA (NASDAQ:MDXH) Price Target at $4.63

Shares of MDxHealth SA (NASDAQ:MDXH) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $4.6250.

A number of brokerages have issued reports on MDXH. William Blair downgraded MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. TD Cowen reissued a “buy” rating and set a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Lake Street Capital reduced their target price on MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Wall Street Zen cut MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, BTIG Research reduced their target price on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, May 14th.

Hedge Funds Weigh In On MDxHealth

Hedge funds have recently made changes to their positions in the company. Intesa Sanpaolo Wealth Management acquired a new position in shares of MDxHealth during the fourth quarter valued at approximately $36,000. GSA Capital Partners LLP acquired a new stake in shares of MDxHealth in the third quarter valued at approximately $48,000. Lido Advisors LLC purchased a new position in MDxHealth during the third quarter worth approximately $48,000. Jefferies Financial Group Inc. purchased a new position in MDxHealth during the third quarter worth approximately $53,000. Finally, Squarepoint Ops LLC purchased a new position in MDxHealth during the fourth quarter worth approximately $51,000.

MDxHealth Trading Down 5.7%

Shares of MDXH stock opened at $0.57 on Monday. The company has a market capitalization of $28.01 million, a P/E ratio of -0.87 and a beta of 1.36. The business’s 50 day moving average is $1.67 and its two-hundred day moving average is $2.83. MDxHealth has a 12-month low of $0.51 and a 12-month high of $5.33.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $23.90 million for the quarter, compared to analysts’ expectations of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%. On average, research analysts predict that MDxHealth will post -0.6 earnings per share for the current fiscal year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.